

Contact: Samantha Harmon
Location: Beaverton, OR
Email: saharmon@najittech.com
Tel: (971) 727-3568
Website: <http://www.najittech.com/>

Company Profile

Industry Sector: Vaccine Market

Company Overview: Najit Technologies, Inc. (NTI) is dedicated to the development of safe and effective vaccines for emerging and re-emerging infectious diseases. Our proprietary vaccine technology will benefit previously underserved and vulnerable populations including the very young, the elderly, and the immunocompromised. With increased safety and immunogenicity, our vaccine platform also better serves the general population. Our strategy is to develop vaccines that fit the unmet needs of these market segments in addition to military and civilian travelers who need safe but highly effective vaccines against potentially life-threatening infectious diseases in endemic countries.

Target Market(s):

Vulnerable populations: infants, elderly, and immunocompromised
 International travelers
 U.S. Military

Key Value Drivers

Technology: HydroVax™ technology represents a novel “first-in-class” approach that utilizes hydrogen peroxide (H₂O₂) to inactivate viruses and other microbes for vaccine development. The key to the HydroVax™ platform is that it kills target microorganisms without damaging important neutralizing epitopes or reducing overall immunogenicity. HydroVax™ is a broadly applicable platform technology that we believe will usher in a new era of advanced vaccine development.

Competitive Advantage: In side-by-side comparisons, HydroVax™ outperforms other forms of virus inactivation for vaccine preparation. Unlike other inactivating agents such as formaldehyde or betapropiolactone (BPL) that are in the public domain, the use of H₂O₂ for vaccine development represents patented technology with a strong IP position. Oxidation of nucleic acids is the mechanism of action underlying HydroVax™ technology and this differs substantially from formaldehyde (a crosslinking agent) and BPL (an alkylating agent), thus providing a significantly improved alternative to these older and outdated methodologies.

Plan & Strategy: Seeking strategic partners to develop/co-develop new vaccines

Management

Leadership:


Mark Slifka, PhD, President and CSO
 Ian Amanna, PhD, Vice President for Research
 Samantha Harmon, MBA, Head of Accounting and Administration

Key Consultants and Advisors:

Ben Del Tito, PhD, Quality Assurance, Del Tito Consulting, LLC
 Peter Patriarca, MD, Clinical Regulatory Compliance, Immuno-VAX, LLC
 Michael Phillips, JD, Corporate and Business Law, Davis Wright Tremaine, LLP

Product Pipeline

We have developed Vero Master Cell Bank (MCB) and Working Cell Bank (WCB) under cGMP conditions and have optimized virus growth conditions and purification strategies for manufacturing several vaccines. An important advantage of this platform technology is the ability to quickly add new vaccine targets to our growing product pipeline.



*Abbreviations: YFV; yellow fever virus, WNV; West Nile virus, CHIKV; chikungunya virus, ZIKV; zika virus, Flu; influenza, Campy; *Campylobacter*.